Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus CHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus CHLOROTHIAZIDE.
ATACAND HCT vs CHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
500 mg to 1000 mg orally or intravenously once or twice daily.
None Documented
None Documented
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateChlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateCandesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal half-life: 45–120 minutes (prolonged in renal impairment); clinical context: short duration requires frequent dosing
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal: ~95% (tubular secretion); Fecal: <5%
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Thiazide Diuretic
Chlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin."